Options for first- and second-line therapy in small cell lung cancer — a workshop discussion
- 31 August 2003
- journal article
- Published by Elsevier in Lung Cancer
- Vol. 41, S37-S41
- https://doi.org/10.1016/s0169-5002(03)90525-3
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- The role of topotecan in treating small cell lung cancer: second-line treatmentLung Cancer, 2003
- Topotecan as first-line therapy for small cell lung cancer.Lung Cancer, 2003
- Paclitaxel, carboplatin, and topotecan in the treatment of patients with small cell lung carcinomaCancer, 2002
- Is Cisplatin Required for the Treatment of Non-Small-Cell Lung Cancer? Experience and Preliminary Results of a Phase I/II Trial with Topotecan and VinorelbineOncology, 2001
- Temozolomide for treating brain metastasesSeminars in Oncology, 2001
- Etoposide Plus Cisplatin With or Without the Combination of 4'-Epidoxorubicin Plus Cyclophosphamide in Treatment of Extensive Small-Cell Lung Cancer: a French Federation of Cancer Institutes Multicenter Phase III Randomized StudyJNCI Journal of the National Cancer Institute, 2001
- Paclitaxel in combination with carboplatin as salvage treatment in refractory small-cell lung cancer (SCLC): A multicenter phase II studyAnnals of Oncology, 2001
- Paclitaxel and Carboplatin in the Treatment of Small-Cell Lung Cancer Patients Resistant to Cyclophosphamide, Doxorubicin, and Etoposide: A Non–Cross-Resistant ScheduleJournal of Clinical Oncology, 1999
- Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung CancerJournal of Clinical Oncology, 1999
- Multiagent chemotherapy, prophylactic neuraxis irradiation, and consolidative irradiation for small cell carcinoma of the lungAmerican Journal of Clinical Oncology, 1985